{"gene":"MICB","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1999,"finding":"MICA and MICB are stress-induced ligands recognized by gamma delta T cells expressing Vdelta1 on tumor cells. Vdelta1 gamma delta T cell lines and clones derived from tumors recognized MICA/B on autologous and heterologous tumor cells without constraints imposed by specific peptide ligands.","method":"T cell recognition assays using tumor-derived Vdelta1 gamma delta T cell lines and clones against autologous and heterologous tumor cells expressing MICA/B","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple tumor-derived T cell lines and clones tested against autologous and heterologous targets, replicated across multiple tumor types","pmids":["10359807"],"is_preprint":false},{"year":2001,"finding":"NKG2D homodimers form stable complexes with monomeric MICA in solution without requiring additional components, and soluble NKG2D also binds to cell surface MICB. MICA glycosylation is not essential but enhances complex formation. Allelic variants of MICA show large differences in NKG2D binding associated with a single amino acid substitution at position 129 in the alpha2 domain.","method":"Solution binding assay (NKG2D homodimers with monomeric MICA), cell surface binding of soluble NKG2D to MICB-expressing cells, allelic variant comparison","journal":"Immunogenetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct reconstitution of NKG2D-MICA complex in solution, mutagenesis-level allelic comparison, multiple orthogonal methods","pmids":["11491531"],"is_preprint":false},{"year":2006,"finding":"MICB is shed by metalloproteases from tumor cells, generating soluble MICB detectable in sera of cancer patients. Cell-bound MICB causes downregulation of surface NKG2D on NK cells, but soluble MICB did not alter NKG2D expression on NK cells in vitro.","method":"Metalloprotease inhibitor assays, ELISA for soluble MICB in patient sera, NK cell NKG2D expression assays with soluble MICB","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metalloprotease inhibitor experiments plus NK receptor downregulation assay, single lab","pmids":["16698441"],"is_preprint":false},{"year":2006,"finding":"NKG2D and MICB undergo intercellular transfer at the cytotoxic NK cell immune synapse (cNK-IS). MICB expressed on target cells induces clustering of NKG2D at the central supramolecular activation cluster. NKG2D transfer depended on binding to MICB. Transfer of MICB to NK cells also occurred, indicating bidirectional exchange. Brief interactions between NK cells and MICB-expressing target cells led to a reduction in NKG2D-dependent NK cytotoxicity.","method":"Live imaging of NK cell immune synapse, fluorescence microscopy, functional cytotoxicity assays with MICB-expressing 721.221 cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — live imaging plus functional cytotoxicity assays, mechanistic specificity controls (other molecules not transferred), single lab with multiple orthogonal methods","pmids":["16849432"],"is_preprint":false},{"year":2007,"finding":"HDAC inhibitor trichostatin A (TsA) increases MICA and MICB expression on leukemic cells by increasing histone H3 acetylation and decreasing HDAC1 association at the MICA and MICB promoters, as demonstrated by chromatin immunoprecipitation (ChIP) assay.","method":"ChIP assay for histone H3 acetylation and HDAC1 occupancy at MICA/MICB promoters; flow cytometry for surface expression; NK cytotoxicity assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP assay directly demonstrating chromatin remodeling at MICB promoter, coupled with functional NK killing assay, single lab","pmids":["17625602"],"is_preprint":false},{"year":2007,"finding":"The MICB promoter contains a CCAAT box binding NF-Y and a GC box binding Sp1, Sp3, and Sp4. A MICB promoter polymorphism involving a 2-bp deletion near the CCAAT box and GC box diminishes Sp1 transcriptional activation, reducing MICB promoter activity 18-fold.","method":"Transcriptional reporter assays, electrophoretic mobility shift assays (EMSA), functional analysis of promoter variants","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted promoter activity by luciferase reporter, EMSA to identify binding proteins, functional mutagenesis of Sp1 site","pmids":["17557375"],"is_preprint":false},{"year":2008,"finding":"Knockdown of Dicer in human cells elicits DNA damage and upregulates MICB expression. Upregulation of MICB by Dicer knockdown is prevented by pharmacological or genetic inhibition of ATM, ATR, or CHK1 kinases, placing MICB upregulation downstream of the DNA damage response pathway.","method":"RNAi knockdown of Dicer, pharmacological and genetic inhibition of ATM/ATR/CHK1, qRT-PCR and flow cytometry for MICB expression","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KD/inhibitor combinations), replicated with pharmacological and genetic approaches, single lab","pmids":["18644891"],"is_preprint":false},{"year":2008,"finding":"5-Aza-2'-deoxycytidine (5-aza-dC) induces MICB expression through promoter DNA demethylation and DNA damage; ATM kinase inhibition partially prevents MICB upregulation, demonstrating that both DNA damage signaling and demethylation contribute to 5-aza-dC-induced MICB expression.","method":"5-aza-dC treatment, bisulfite sequencing for promoter methylation, ATM inhibitor (KU55933) and ATM siRNA knockdown, flow cytometry","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter methylation analysis plus genetic/pharmacological ATM inhibition, single lab","pmids":["18395517"],"is_preprint":false},{"year":2009,"finding":"microRNAs from multiple herpesviruses (HCMV, KSHV, EBV) directly target MICB mRNA at different but adjacent sites to repress its expression, enabling NK cell evasion. Despite no sequence homology among the viral miRNAs, they are functionally conserved in MICB suppression during authentic viral infection.","method":"Reporter assays with MICB 3'UTR, authentic viral infection experiments, NK cell killing assays","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct targeting of MICB 3'UTR by multiple viral miRNAs demonstrated by reporter assay and authentic infection, replicated across three different herpesviruses","pmids":["19380116"],"is_preprint":false},{"year":2010,"finding":"Crystal structure of HCMV UL16 in complex with MICB at 1.8 Å resolution reveals that UL16 uses a three-stranded beta-sheet to engage the alpha-helical surface of the MICB platform domain, mimicking the NKG2D binding mode. UL16 binds MICB with nanomolar affinity (12-66 nM, by SPR). The inability of UL16 to bind MICA is due to a single residue difference: glutamine at position 169 in MICB (versus arginine in MICA) is critical for UL16 binding.","method":"X-ray crystallography (1.8 Å), surface plasmon resonance binding assays, mutational analysis of key residues","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure at high resolution combined with SPR quantitative binding and mutational validation, single study with multiple orthogonal methods","pmids":["20090832"],"is_preprint":false},{"year":2011,"finding":"HHV-7 U21 protein downregulates the surface expression of MICB (and MICA), resulting in reduction of NK-mediated cytotoxicity. U21 can bind to ULBP1 and reroute it to the lysosomal compartment; the mechanism of MICA/B downregulation may involve similar lysosomal redirection.","method":"Flow cytometry for surface MICB/MICA expression in U21-expressing cells, NK cytotoxicity assays","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — flow cytometry showing surface downregulation plus NK killing functional assay, mechanism for MICB not as directly demonstrated as for ULBP1","pmids":["22102813"],"is_preprint":false},{"year":2012,"finding":"miR-10b directly binds the 3'UTR of MICB mRNA and downregulates MICB surface expression. Antagonizing miR-10b enhanced NKG2D-mediated NK killing of tumor cells in vitro and tumor clearance in vivo; overexpression of miR-10b downregulated MICB and impaired NK cell elimination of tumor cells.","method":"Luciferase reporter assays with MICB 3'UTR, miR-10b overexpression and antagonism, flow cytometry, in vitro and in vivo NK killing assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct 3'UTR reporter validation plus loss- and gain-of-function in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["22915757"],"is_preprint":false},{"year":2013,"finding":"HBsAg overexpression in HepG2 cells induces cellular miRNAs that repress MICA and MICB expression by targeting their 3'UTRs. Inhibiting these HBsAg-induced miRNAs partially restores MICA/MICB expression and increases NK cell-mediated cytolysis of HCC cells.","method":"miRNA profiling, 3'UTR reporter assays, miRNA inhibitors, NK cell cytotoxicity assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'UTR reporter validation plus functional NK killing assay with rescue by miRNA inhibitors, single lab","pmids":["23917076"],"is_preprint":false},{"year":2013,"finding":"ADAM15 mediates MICB ectodomain shedding in PANC-1 pancreatic cancer cells. Knockdown of ADAM15 upregulates cell surface MICB and reduces soluble MICB in culture supernatant. Gemcitabine suppresses ADAM15 expression, leading to increased surface MICB and decreased soluble MICB without changing MICB mRNA levels.","method":"ADAM15 siRNA knockdown, flow cytometry for surface MICB, ELISA for soluble MICB, qRT-PCR, gemcitabine treatment","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown of specific sheddase with direct measurement of surface vs. soluble MICB, mRNA control confirms post-translational mechanism, single lab","pmids":["23314034"],"is_preprint":false},{"year":2014,"finding":"Six RNA-binding proteins (RBPs) that bind and regulate MICB expression were identified by unbiased RNA pull-down combined with mass spectrometry. At least two of the identified RBPs function during genotoxic stress to regulate MICB.","method":"RNA pull-down with MICB mRNA, mass spectrometry, functional validation of RBP knockdowns during genotoxic stress","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — unbiased pull-down plus mass spectrometry with functional validation, single lab","pmids":["24924487"],"is_preprint":false},{"year":2014,"finding":"Valproic acid (VPA), an HDAC inhibitor, upregulates MICA and MICB surface expression on pancreatic cancer cells via the PI3K/Akt signaling pathway. This effect is blocked by the PI3K inhibitor LY294002 or siRNA targeting PI3KCA, and sensitizes cancer cells to NK-mediated killing in vitro and in vivo.","method":"PI3K inhibitor treatment (LY294002), siRNA knockdown of PI3KCA, flow cytometry for MICB surface expression, qRT-PCR, NK cytotoxicity assays, xenograft experiments","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement by pharmacological and genetic inhibition with functional NK killing readout, single lab","pmids":["24885711"],"is_preprint":false},{"year":2016,"finding":"The RNA-binding protein IMP3 directly interacts with ULBP2 mRNA to destabilize it, and indirectly targets MICB through a mechanistically distinct pathway. IMP3-mediated regulation of MICB leads to impaired NK cell recognition of transformed cells.","method":"RNA pull-down, mRNA stability assays, IMP3 knockdown and overexpression, flow cytometry for MICB surface expression, NK cell killing assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RBP-RNA interaction for ULBP2, indirect MICB regulation with functional NK killing readout; MICB mechanism less directly defined, single lab","pmids":["26982091"],"is_preprint":false},{"year":2017,"finding":"Vigilin, a multifunctional RNA-binding protein, binds to the 5'UTR of MICB mRNA and negatively regulates MICB expression. Vigilin knockdown in target cells increases MICB surface expression and enhances NK cell activation against those cells.","method":"RNA pull-down of MICB 5'UTR followed by mass spectrometry, vigilin knockdown, flow cytometry for MICB surface expression, NK cell activation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pull-down plus mass spectrometry with functional validation by KD and NK activation assay, single lab","pmids":["28356383"],"is_preprint":false},{"year":2017,"finding":"STAT3 inhibition by STA21 increases MICB cell surface expression and soluble MICB secretion by gastric adenocarcinoma cells. Recombinant soluble MICB decreases NKG2D receptor levels on NK and CD8+ T cells and impairs their cytotoxic function. MICB shedding in this context was not affected by metalloprotease inhibition, suggesting a non-metalloprotease secretory pathway.","method":"STAT3 inhibitor (STA21) treatment, flow cytometry, ELISA for soluble MICB, metalloprotease inhibitor assays, NK cell cytotoxicity assays","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological STAT3 inhibition with mechanistic controls (metalloprotease inhibitor negative result), functional NK killing assay, single lab","pmids":["28917678"],"is_preprint":false},{"year":2017,"finding":"MICB and MICA expression is predominantly intracellular in both tumor and normal tissue, with only occasional evidence of cell membrane localization. No qualitative differences in cell surface expression were observed between tumor and MICA/B-expressing normal epithelia.","method":"Standard and confocal immunofluorescence microscopy using well-characterized antibodies on multiple human tumor and normal tissue samples","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic direct localization by confocal microscopy across multiple tissue types, single lab","pmids":["28334733"],"is_preprint":false},{"year":2017,"finding":"DAC (decitabine) treatment of AML cells increases TIMP3 expression by demethylation of its promoter, and TIMP3 (an ADAM17 inhibitor) inhibits shedding of MICB (and MICA and ULBP2), reducing soluble NKG2D ligands and enhancing NK cell-mediated immune recognition of AML cells.","method":"Hypomethylating agent treatment, ADAM17 inhibitor (TIMP3) overexpression, ELISA for soluble MICB, NK cell killing assays, methylation analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway from demethylation to TIMP3 to ADAM17 inhibition to reduced MICB shedding, functional NK killing readout, single lab","pmids":["28404876"],"is_preprint":false},{"year":2018,"finding":"Antibodies targeting the MICA α3 domain (site of proteolytic shedding) prevent proteolytic shedding of both MICA and MICB from human cancer cells, maintain cell surface MICA/MICB, inhibit tumor growth in immunocompetent mouse models, and reactivate NK cell antitumor immunity via NKG2D and CD16 Fc receptors.","method":"Rational antibody design targeting α3 domain, flow cytometry for surface MICA/MICB, in vivo tumor growth assays in immunocompetent mice, NK cell depletion experiments, humanized mouse model","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic targeting of shedding site with multiple in vivo models, NK depletion confirming effector mechanism, replicated across multiple tumor models","pmids":["29599246"],"is_preprint":false},{"year":2018,"finding":"miR-34a plays a dual role in MICB regulation in hepatocytes: it can both increase MICB expression by upregulating ATR protein kinase and decrease MICB expression by downregulating the transcription factor E2F1. The net effect on MICB depends on endogenous E2F1 levels, with miR-34a promoting MICB in cells with low E2F1 (normal hepatocytes) but not in cells with high E2F1 (many HCC cells).","method":"miR-34a overexpression, ATR and E2F1 knockdown, flow cytometry, luciferase reporter assays, NK cell killing assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic perturbations (miRNA OE, ATR/E2F1 KD) with reporter assays and functional NK killing, single lab","pmids":["30256916"],"is_preprint":false},{"year":2018,"finding":"MG132 (proteasome inhibitor) selectively upregulates MICB transcription in A549 lung cancer cells by acting at the 480-bp MICB upstream promoter. This upregulation requires ATM kinase, ATR kinase, and PI3K activity, as inhibitors of these kinases block MG132-induced MICB upregulation; MG132 activates CHK2 phosphorylation (a DNA damage marker), placing MICB upregulation downstream of the DNA damage response.","method":"MICB promoter luciferase reporter assay, ATM inhibitor (KU-55933), wortmannin, caffeine treatment, CHK2 phosphorylation assay, NK cytotoxicity blocking assays","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay with pharmacological epistasis analysis and DNA damage marker, single lab","pmids":["30483783"],"is_preprint":false},{"year":2019,"finding":"Liver X receptor (LXR) activation upregulates MICB expression in multiple myeloma cells through inhibition of MICB protein degradation in lysosomes (post-translational stabilization), whereas MICA is regulated at the transcriptional level. LXR activation enhances NK cell-mediated killing of MM cells.","method":"LXR agonist treatment, MICB protein stability assays with lysosomal inhibitors, MICA promoter activity assays, NK cell killing assays, flow cytometry","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic distinction between MICA transcriptional vs. MICB lysosomal post-translational regulation using inhibitors and functional assays, single lab","pmids":["31125275"],"is_preprint":false},{"year":2013,"finding":"Diverse allelic MICB proteins differentially bind the HCMV immunoevasin UL16. MICB*008, which contains methionine and asparagine at positions 98 and 113 in the alpha2 domain, shows decreased binding to UL16 compared to MICB*003, *004, and *00502 (which contain isoleucine and aspartic acid at those positions). UL16 variant strains did not affect binding activities.","method":"Production of soluble Fc-fusion UL16 proteins from four HCMV strains, stable cell lines expressing four MICB alleles, flow cytometry-based binding assays","journal":"Journal of microbiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — allele-specific binding by flow cytometry with multiple alleles and UL16 variants, functional interpretation regarding immune evasion, single lab","pmids":["23625227"],"is_preprint":false},{"year":2020,"finding":"Missense variant MICB D136N (rs in MICB) expressed in cultured cells results in reduced surface MICB and reduced NKG2D ligation relative to wild-type MICB. Coculture of MICB D136N-expressing cells with NK cells results in less NKG2D activation and less susceptibility to NK cell killing compared to wild-type MICB-expressing cells.","method":"Expression of MICB missense variant protein in cultured cells, flow cytometry for surface MICB, NKG2D activation assays, NK cell coculture killing assays, ex vivo BAL analysis","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional characterization of missense variant with direct NKG2D activation assay and NK killing, supported by clinical association data, single lab","pmids":["37878820"],"is_preprint":false},{"year":2003,"finding":"Transgenic mice ubiquitously expressing human MICB develop transient hyperkeratosis of the epidermis with infiltrating inflammatory cells, and a 50% increase in white blood cells, indicating that MICB expression in vivo is associated with skin inflammation and leukocytosis.","method":"Transgenic mouse generation with ubiquitous MICB promoter, histopathological analysis, complete blood count","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic in vivo loss-of-function/gain-of-function with histopathological phenotype, but limited mechanistic resolution of pathway, single lab","pmids":["12753668"],"is_preprint":false},{"year":2017,"finding":"Nine novel miRNAs were identified that regulate MICB expression via both its 3'UTR and 5'UTR sequences in human cancer cells. Mutation of miRNA binding sites in both UTRs increased luciferase reporter activity, and overexpression/inhibition of candidate miRNAs decreased/increased MICB protein expression on cell surfaces.","method":"Luciferase reporter assays with MICB 3'UTR and 5'UTR constructs, site-directed mutagenesis of miRNA binding sites, miRNA overexpression and inhibition, flow cytometry","journal":"Genes","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — reporter assay plus mutagenesis of binding sites plus gain/loss-of-function, single lab","pmids":["28850101"],"is_preprint":false}],"current_model":"MICB is a stress-inducible MHC class I-related cell surface glycoprotein that serves as a ligand for the activating immunoreceptor NKG2D on NK cells, CD8+ T cells, and gamma-delta T cells; its expression is regulated at transcriptional level by Sp1/NF-Y binding to its promoter (modulated by HDAC activity and DNA methylation), at post-transcriptional level by multiple RNA-binding proteins (including vigilin via 5'UTR and IMP3) and miRNAs (including viral herpesvirus miRNAs, miR-10b, and cellular miRNAs targeting its 3'UTR), and at the protein level by metalloprotease-mediated ectodomain shedding (involving ADAM15 and ADAM17/TIMP3 axis), lysosomal degradation (regulated by LXR/cholesterol), and intracellular retention by viral immunoevasins such as HCMV UL16 (which engages the MICB alpha-helical platform domain at a glutamine-169-dependent interface); cell surface MICB activates NKG2D to trigger NK cytotoxicity, while proteolytic shedding generates soluble MICB that contributes to immune evasion by reducing NKG2D ligand density on tumor cells."},"narrative":{"mechanistic_narrative":"MICB is a stress-inducible MHC class I-related cell surface glycoprotein that functions as an activating ligand for the immunoreceptor NKG2D, engaging gamma-delta T cells, NK cells, and CD8+ T cells to trigger cytotoxicity against stressed and transformed cells [PMID:10359807, PMID:11491531, PMID:16849432]. NKG2D homodimers bind monomeric MICB directly, and at the cytotoxic immune synapse MICB on target cells clusters NKG2D into the central supramolecular activation cluster, with bidirectional intercellular transfer of both molecules tuning the NK cytotoxic response [PMID:11491531, PMID:16849432]. MICB expression is controlled at multiple regulatory layers. Transcriptionally, the MICB promoter is driven by Sp1/Sp3/Sp4 at a GC box and NF-Y at a CCAAT box, and is modulated by chromatin state, since HDAC inhibition raises histone H3 acetylation and lowers HDAC1 occupancy at the promoter, while promoter demethylation also induces expression [PMID:17557375, PMID:17625602, PMID:18395517]; genotoxic stress couples MICB induction to the ATM/ATR/CHK1 DNA damage response [PMID:18644891, PMID:30483783]. Post-transcriptionally, MICB mRNA is repressed by RNA-binding proteins acting through its 5'UTR (vigilin) and by IMP3, and by numerous miRNAs—including functionally convergent herpesviral miRNAs (HCMV, KSHV, EBV) and cellular miRNAs such as miR-10b—targeting its 3'UTR and 5'UTR [PMID:28356383, PMID:26982091, PMID:19380116, PMID:22915757, PMID:28850101]. At the protein level, MICB is shed from the cell surface by metalloproteases including ADAM15 and the ADAM17/TIMP3 axis, generating soluble MICB that contributes to immune evasion; antibodies blocking the shedding site preserve surface MICB and reactivate NK antitumor immunity in vivo [PMID:23314034, PMID:28404876, PMID:16698441, PMID:29599246]. Viral immunoevasins additionally subvert MICB: HCMV UL16 engages the alpha-helical platform domain via a glutamine-169-dependent interface that mimics the NKG2D binding mode and retains MICB intracellularly, with allelic MICB variants differing in UL16 binding [PMID:20090832, PMID:23625227]. A naturally occurring MICB D136N missense variant reduces surface expression and NKG2D ligation, blunting NK killing [PMID:37878820].","teleology":[{"year":1999,"claim":"Established MICB as a stress-induced cell surface ligand recognized by the immune system, defining its role in immune surveillance of tumors independent of peptide presentation.","evidence":"Vdelta1 gamma-delta T cell recognition assays against autologous and heterologous tumor cells expressing MICA/B","pmids":["10359807"],"confidence":"High","gaps":["Did not identify the activating receptor responsible for recognition","Did not resolve how MICB induction is triggered"]},{"year":2001,"claim":"Identified NKG2D as the receptor binding MICB directly, providing the molecular basis for MICB-driven immune activation.","evidence":"Solution binding of NKG2D homodimers to MICA, soluble NKG2D binding to surface MICB, allelic variant comparison","pmids":["11491531"],"confidence":"High","gaps":["Affinity and structural detail of NKG2D-MICB itself not fully quantified","Downstream signaling consequences not addressed"]},{"year":2006,"claim":"Showed MICB engagement at the NK immune synapse drives NKG2D clustering and bidirectional transfer, revealing a self-limiting feature of MICB-mediated activation, while metalloprotease shedding generates soluble MICB in patient sera.","evidence":"Live synapse imaging, cytotoxicity assays with MICB-expressing target cells; metalloprotease inhibitor assays and serum ELISA","pmids":["16849432","16698441"],"confidence":"High","gaps":["Identity of the shedding metalloprotease not defined","Functional consequence of soluble MICB on NK cells unclear (no NKG2D downregulation observed)"]},{"year":2007,"claim":"Defined the transcriptional architecture of the MICB promoter (Sp1/NF-Y) and demonstrated chromatin-level control via histone acetylation and HDAC1 occupancy.","evidence":"Promoter reporter assays, EMSA, promoter polymorphism analysis; ChIP for H3 acetylation and HDAC1 at the MICB promoter","pmids":["17557375","17625602"],"confidence":"High","gaps":["Signals that recruit HDAC1 versus activators not defined","Connection between promoter occupancy and physiological stress unaddressed"]},{"year":2008,"claim":"Placed MICB induction downstream of the ATM/ATR/CHK1 DNA damage response and linked it to promoter demethylation, establishing genotoxic stress as a trigger of MICB surface expression.","evidence":"Dicer knockdown with ATM/ATR/CHK1 inhibition; 5-aza-dC treatment with bisulfite sequencing and ATM inhibition","pmids":["18644891","18395517"],"confidence":"High","gaps":["Molecular step coupling DDR kinases to MICB transcription not identified","Relative contribution of transcriptional versus post-transcriptional DDR control unresolved"]},{"year":2009,"claim":"Revealed convergent post-transcriptional immune evasion: structurally unrelated herpesviral miRNAs target the MICB 3'UTR to suppress NK recognition during infection.","evidence":"MICB 3'UTR reporter assays, authentic HCMV/KSHV/EBV infection, NK killing assays","pmids":["19380116"],"confidence":"High","gaps":["Selective pressure driving 3'UTR targeting not defined","Interplay with host miRNA regulation unaddressed"]},{"year":2010,"claim":"Defined at atomic resolution how the HCMV UL16 immunoevasin captures MICB via the NKG2D-mimicking platform domain, pinpointing glutamine-169 as the allele-specific determinant.","evidence":"X-ray crystallography at 1.8 A, surface plasmon resonance, mutational analysis","pmids":["20090832"],"confidence":"High","gaps":["Intracellular retention mechanism downstream of binding not structurally resolved","Generalizability to other immunoevasins not established here"]},{"year":2013,"claim":"Expanded the regulatory repertoire to specific sheddases and additional viral evaders, and established allele-dependent UL16 binding among MICB variants.","evidence":"ADAM15 knockdown with surface/soluble MICB measurement; HBsAg-induced miRNA profiling; HHV-7 U21 surface downregulation; allele-specific UL16 Fc-fusion binding assays","pmids":["23314034","23917076","22102813","23625227"],"confidence":"Medium","gaps":["Whether multiple sheddases act redundantly on MICB unresolved","U21 lysosomal mechanism for MICB inferred from ULBP1, not directly shown"]},{"year":2016,"claim":"Identified RNA-binding proteins (including vigilin via the 5'UTR and IMP3) as direct post-transcriptional repressors of MICB linking RNA metabolism to NK evasion.","evidence":"RNA pull-down with mass spectrometry, knockdown, surface MICB flow cytometry, NK assays (multiple studies)","pmids":["24924487","26982091","28356383"],"confidence":"Medium","gaps":["IMP3 effect on MICB is indirect and mechanistically undefined","Coordination among the multiple RBPs not established"]},{"year":2017,"claim":"Refined the spatial and signaling control of MICB, showing predominantly intracellular localization, STAT3- and PI3K/Akt-linked modulation, and extensive multi-miRNA targeting of both UTRs.","evidence":"Confocal microscopy of tumor/normal tissue; STAT3 and PI3K inhibitor studies with NK assays; dual-UTR luciferase reporters with binding-site mutagenesis","pmids":["28334733","28917678","24885711","28850101"],"confidence":"Medium","gaps":["Mechanism routing MICB to the surface from intracellular pools not defined","Non-metalloprotease MICB secretion pathway uncharacterized"]},{"year":2018,"claim":"Established protein-level stabilization strategies and therapeutic proof-of-concept: blocking shedding or stabilizing MICB protein preserves surface ligand and reactivates antitumor immunity.","evidence":"Anti-alpha3-domain shedding-blocking antibodies in immunocompetent mice with NK depletion; miR-34a/ATR/E2F1 perturbations; (2019) LXR-driven lysosomal MICB stabilization","pmids":["29599246","30256916","31125275"],"confidence":"High","gaps":["Lysosomal degradation machinery for MICB not molecularly defined","Context-dependence of miR-34a dual effect across tumor types unresolved"]},{"year":2020,"claim":"Demonstrated that natural MICB coding variation functionally tunes NKG2D ligation and NK killing, linking MICB genotype to immune outcomes.","evidence":"Expression of MICB D136N missense variant, surface flow cytometry, NKG2D activation and NK coculture killing assays","pmids":["37878820"],"confidence":"Medium","gaps":["Molecular basis for reduced surface expression of D136N not defined","Population-level immune consequences not established mechanistically"]},{"year":null,"claim":"How the diverse transcriptional, RNA-binding, miRNA, shedding, and trafficking inputs are integrated to set MICB surface density on a given stressed cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model coupling DDR signaling to specific surface-trafficking steps","Mechanism controlling intracellular retention versus surface display of MICB undefined","Relative quantitative contribution of each regulatory layer in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,3,26]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,3,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[19,24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,8]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,7,23]}],"complexes":[],"partners":["KLRK1","UL16","ADAM15","ADAM17","TIMP3","HDLBP","IGF2BP3","SP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q29980","full_name":"MHC class I polypeptide-related sequence B","aliases":[],"length_aa":383,"mass_kda":42.6,"function":"Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8+ alphabeta T-cells (PubMed:11491531, PubMed:11777960). Up-regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells resulting in a range of immune effector functions, such as cytotoxicity and cytokine production","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q29980/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MICB","classification":"Not Classified","n_dependent_lines":32,"n_total_lines":1208,"dependency_fraction":0.026490066225165563},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MICB","total_profiled":1310},"omim":[{"mim_id":"614371","title":"DENGUE VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/614371"},{"mim_id":"611817","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY K, MEMBER 1; KLRK1","url":"https://www.omim.org/entry/611817"},{"mim_id":"605699","title":"UL16-BINDING PROTEIN 3; ULBP3","url":"https://www.omim.org/entry/605699"},{"mim_id":"605698","title":"UL16-BINDING PROTEIN 2; ULBP2","url":"https://www.omim.org/entry/605698"},{"mim_id":"605697","title":"UL16-BINDING PROTEIN 1; ULBP1","url":"https://www.omim.org/entry/605697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":9.4}],"url":"https://www.proteinatlas.org/search/MICB"},"hgnc":{"alias_symbol":["PERB11.2"],"prev_symbol":[]},"alphafold":{"accession":"Q29980","domains":[{"cath_id":"3.30.500.10","chopping":"25-200","consensus_level":"high","plddt":92.2753,"start":25,"end":200},{"cath_id":"2.60.40.10","chopping":"206-293","consensus_level":"high","plddt":93.3194,"start":206,"end":293}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29980","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q29980-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q29980-F1-predicted_aligned_error_v6.png","plddt_mean":78.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MICB","jax_strain_url":"https://www.jax.org/strain/search?query=MICB"},"sequence":{"accession":"Q29980","fasta_url":"https://rest.uniprot.org/uniprotkb/Q29980.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q29980/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29980"}},"corpus_meta":[{"pmid":"10359807","id":"PMC_10359807","title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10359807","citation_count":832,"is_preprint":false},{"pmid":"29599246","id":"PMC_29599246","title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29599246","citation_count":387,"is_preprint":false},{"pmid":"19380116","id":"PMC_19380116","title":"Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells.","date":"2009","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/19380116","citation_count":386,"is_preprint":false},{"pmid":"11491531","id":"PMC_11491531","title":"Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11491531","citation_count":377,"is_preprint":false},{"pmid":"12569559","id":"PMC_12569559","title":"Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12569559","citation_count":196,"is_preprint":false},{"pmid":"11429322","id":"PMC_11429322","title":"MICA and MICB genes: can the enigma of their polymorphism be resolved?","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11429322","citation_count":161,"is_preprint":false},{"pmid":"16698441","id":"PMC_16698441","title":"Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16698441","citation_count":121,"is_preprint":false},{"pmid":"10523017","id":"PMC_10523017","title":"Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10523017","citation_count":120,"is_preprint":false},{"pmid":"32209637","id":"PMC_32209637","title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32209637","citation_count":112,"is_preprint":false},{"pmid":"22915757","id":"PMC_22915757","title":"MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22915757","citation_count":108,"is_preprint":false},{"pmid":"16636811","id":"PMC_16636811","title":"Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16636811","citation_count":104,"is_preprint":false},{"pmid":"17625602","id":"PMC_17625602","title":"Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17625602","citation_count":99,"is_preprint":false},{"pmid":"28334733","id":"PMC_28334733","title":"MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28334733","citation_count":92,"is_preprint":false},{"pmid":"17565371","id":"PMC_17565371","title":"In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17565371","citation_count":83,"is_preprint":false},{"pmid":"16849432","id":"PMC_16849432","title":"Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16849432","citation_count":74,"is_preprint":false},{"pmid":"9321430","id":"PMC_9321430","title":"Allelic variants of the human MHC class I chain-related B gene (MICB).","date":"1997","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9321430","citation_count":74,"is_preprint":false},{"pmid":"18644891","id":"PMC_18644891","title":"Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18644891","citation_count":68,"is_preprint":false},{"pmid":"11443095","id":"PMC_11443095","title":"Competence repression under oxygen limitation through the two-component MicAB signal-transducing system in Streptococcus pneumoniae and involvement of the PAS domain of MicB.","date":"2001","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11443095","citation_count":63,"is_preprint":false},{"pmid":"12022360","id":"PMC_12022360","title":"MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis.","date":"2002","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12022360","citation_count":58,"is_preprint":false},{"pmid":"17557375","id":"PMC_17557375","title":"Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17557375","citation_count":57,"is_preprint":false},{"pmid":"24885711","id":"PMC_24885711","title":"Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24885711","citation_count":55,"is_preprint":false},{"pmid":"18395517","id":"PMC_18395517","title":"Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18395517","citation_count":53,"is_preprint":false},{"pmid":"16641608","id":"PMC_16641608","title":"Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies.","date":"2006","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16641608","citation_count":46,"is_preprint":false},{"pmid":"11782275","id":"PMC_11782275","title":"MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11782275","citation_count":44,"is_preprint":false},{"pmid":"26982091","id":"PMC_26982091","title":"The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26982091","citation_count":44,"is_preprint":false},{"pmid":"20090832","id":"PMC_20090832","title":"Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.","date":"2010","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/20090832","citation_count":43,"is_preprint":false},{"pmid":"11169252","id":"PMC_11169252","title":"Wide distribution of the MICA-MICB null haplotype in East Asians.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11169252","citation_count":41,"is_preprint":false},{"pmid":"22102813","id":"PMC_22102813","title":"The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22102813","citation_count":41,"is_preprint":false},{"pmid":"28404876","id":"PMC_28404876","title":"Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28404876","citation_count":39,"is_preprint":false},{"pmid":"23917076","id":"PMC_23917076","title":"Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23917076","citation_count":39,"is_preprint":false},{"pmid":"17003176","id":"PMC_17003176","title":"MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility.","date":"2006","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17003176","citation_count":37,"is_preprint":false},{"pmid":"11034563","id":"PMC_11034563","title":"On the MICA deleted-MICB null, HLA-B*4801 haplotype.","date":"2000","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11034563","citation_count":37,"is_preprint":false},{"pmid":"12175734","id":"PMC_12175734","title":"High resolution molecular phototyping of MICA and MICB alleles using sequence specific primers.","date":"2002","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12175734","citation_count":35,"is_preprint":false},{"pmid":"21762746","id":"PMC_21762746","title":"Association of MICA and MICB alleles with symptomatic dengue infection.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21762746","citation_count":34,"is_preprint":false},{"pmid":"17561376","id":"PMC_17561376","title":"Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/17561376","citation_count":34,"is_preprint":false},{"pmid":"9712354","id":"PMC_9712354","title":"Microsatellite polymorphism within the MICB gene among Japanese patients with Behçet's disease.","date":"1998","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9712354","citation_count":34,"is_preprint":false},{"pmid":"16923796","id":"PMC_16923796","title":"Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16923796","citation_count":33,"is_preprint":false},{"pmid":"9694358","id":"PMC_9694358","title":"Sequencing-based typing reveals six novel MHC class I chain-related gene B (MICB) alleles.","date":"1998","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9694358","citation_count":32,"is_preprint":false},{"pmid":"21477352","id":"PMC_21477352","title":"Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells.","date":"2011","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/21477352","citation_count":28,"is_preprint":false},{"pmid":"12671735","id":"PMC_12671735","title":"MICB typing by PCR amplification with sequence specific primers.","date":"2003","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12671735","citation_count":28,"is_preprint":false},{"pmid":"21036725","id":"PMC_21036725","title":"Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21036725","citation_count":28,"is_preprint":false},{"pmid":"24924487","id":"PMC_24924487","title":"RNA-binding proteins regulate the expression of the immune activating ligand MICB.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24924487","citation_count":27,"is_preprint":false},{"pmid":"31125275","id":"PMC_31125275","title":"Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31125275","citation_count":27,"is_preprint":false},{"pmid":"24884822","id":"PMC_24884822","title":"A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24884822","citation_count":27,"is_preprint":false},{"pmid":"16101831","id":"PMC_16101831","title":"The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy.","date":"2005","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16101831","citation_count":27,"is_preprint":false},{"pmid":"21664939","id":"PMC_21664939","title":"Characterization of the major histocompatibility complex class I chain-related gene B (MICB) polymorphism in a northern Chinese Han population: the identification of a new MICB allele, MICB*023.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21664939","citation_count":26,"is_preprint":false},{"pmid":"20566410","id":"PMC_20566410","title":"HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation.","date":"2010","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20566410","citation_count":25,"is_preprint":false},{"pmid":"15089901","id":"PMC_15089901","title":"Association of MHC class I related gene B (MICB) to celiac disease.","date":"2004","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15089901","citation_count":25,"is_preprint":false},{"pmid":"11862397","id":"PMC_11862397","title":"Alu polymorphism within the MICB gene and association with HLA-B alleles.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11862397","citation_count":24,"is_preprint":false},{"pmid":"18588574","id":"PMC_18588574","title":"Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility.","date":"2008","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/18588574","citation_count":22,"is_preprint":false},{"pmid":"28850101","id":"PMC_28850101","title":"5'-UTR and 3'-UTR Regulation of MICB Expression in Human Cancer Cells by Novel microRNAs.","date":"2017","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/28850101","citation_count":21,"is_preprint":false},{"pmid":"24962621","id":"PMC_24962621","title":"Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24962621","citation_count":21,"is_preprint":false},{"pmid":"18505429","id":"PMC_18505429","title":"Associations of MICB with cervical cancer in north-eastern Thais: identification of major histocompatibility complex class I chain-related gene B motifs influencing natural killer cell activation.","date":"2008","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18505429","citation_count":21,"is_preprint":false},{"pmid":"27028549","id":"PMC_27028549","title":"MICA, MICB Polymorphisms and Linkage Disequilibrium with HLA-B in a Chinese Mongolian Population.","date":"2016","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27028549","citation_count":21,"is_preprint":false},{"pmid":"21554252","id":"PMC_21554252","title":"MICB polymorphisms and haplotypes with MICA and HLA alleles in Koreans.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21554252","citation_count":20,"is_preprint":false},{"pmid":"11881819","id":"PMC_11881819","title":"MICA and MICB microsatellite alleles in HLA extended haplotypes.","date":"2001","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11881819","citation_count":20,"is_preprint":false},{"pmid":"12242594","id":"PMC_12242594","title":"High frequency of MIC null haplotype (HLA-B48-MICA-del-MICB*0107 N) in the Angaite Amerindian community in Paraguay.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12242594","citation_count":20,"is_preprint":false},{"pmid":"10746790","id":"PMC_10746790","title":"Three novel MICB alleles.","date":"2000","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10746790","citation_count":19,"is_preprint":false},{"pmid":"17181741","id":"PMC_17181741","title":"MICA and MICB overexpression in oral squamous cell carcinoma.","date":"2007","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17181741","citation_count":18,"is_preprint":false},{"pmid":"28578917","id":"PMC_28578917","title":"STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28578917","citation_count":17,"is_preprint":false},{"pmid":"22609444","id":"PMC_22609444","title":"MICB polymorphism in a southern Chinese Han population: the identification of two new MICB alleles, MICB*005:06 and MICB*026.","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22609444","citation_count":17,"is_preprint":false},{"pmid":"11929594","id":"PMC_11929594","title":"The nucleotide diversity of MICA and MICB suggests the effect of overdominant selection.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11929594","citation_count":17,"is_preprint":false},{"pmid":"28944101","id":"PMC_28944101","title":"Soluble MICB in Plasma and Urine Explains Population Expansions of NKG2D+CD4 T Cells Inpatients with Juvenile-Onset Systemic Lupus Erythematosus.","date":"2017","source":"Open journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28944101","citation_count":14,"is_preprint":false},{"pmid":"11929593","id":"PMC_11929593","title":"Linkage disequilibria between HLA-B, C1_4_1, MICA and MICB.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11929593","citation_count":14,"is_preprint":false},{"pmid":"15304009","id":"PMC_15304009","title":"Study on the haplotypes of MICA and MICB microsatellite and HLA-B locus in the Guangzhou Han population.","date":"2004","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/15304009","citation_count":13,"is_preprint":false},{"pmid":"23549730","id":"PMC_23549730","title":"Distribution of MICB diversity in the Zhejiang Han population: PCR sequence-based typing for exons 2-6 and identification of five novel MICB alleles.","date":"2013","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23549730","citation_count":13,"is_preprint":false},{"pmid":"12466900","id":"PMC_12466900","title":"Alternatively spliced forms of MICA and MICB lacking exon 3 in a human cell line and evidence of presence of similar RNA in human peripheral blood mononuclear cells.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12466900","citation_count":12,"is_preprint":false},{"pmid":"16679067","id":"PMC_16679067","title":"MICB microsatellite polymorphism is associated with ulcerative colitis in Chinese population.","date":"2006","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16679067","citation_count":12,"is_preprint":false},{"pmid":"32286503","id":"PMC_32286503","title":"Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status.","date":"2020","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32286503","citation_count":12,"is_preprint":false},{"pmid":"10583461","id":"PMC_10583461","title":"Novel intronic variants of MICB (MHC class I chain-related gene B).","date":"1999","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10583461","citation_count":12,"is_preprint":false},{"pmid":"30256916","id":"PMC_30256916","title":"MicroRNA-34a promotes MICB expression in hepatocytes.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30256916","citation_count":11,"is_preprint":false},{"pmid":"30483783","id":"PMC_30483783","title":"MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30483783","citation_count":11,"is_preprint":false},{"pmid":"23314034","id":"PMC_23314034","title":"ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/23314034","citation_count":11,"is_preprint":false},{"pmid":"27026046","id":"PMC_27026046","title":"MMP9 Promoter Polymorphism (-1562 C/T) Does not Affect the Serum Levels of Soluble MICB and MICA in Breast Cancer.","date":"2016","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/27026046","citation_count":11,"is_preprint":false},{"pmid":"37878820","id":"PMC_37878820","title":"MICB Genomic Variant Is Associated with NKG2D-mediated Acute Lung Injury and Death.","date":"2024","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37878820","citation_count":10,"is_preprint":false},{"pmid":"33599111","id":"PMC_33599111","title":"High-throughput genotyping of HLA-G, HLA-F, MICA, and MICB and analysis of frequency distributions in healthy blood donors from Catalonia.","date":"2021","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/33599111","citation_count":10,"is_preprint":false},{"pmid":"33835601","id":"PMC_33835601","title":"Associations of high-resolution-typing-defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with Oral Squamous Cell Carcinoma in Bulgarian patients.","date":"2021","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33835601","citation_count":9,"is_preprint":false},{"pmid":"34682758","id":"PMC_34682758","title":"Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34682758","citation_count":9,"is_preprint":false},{"pmid":"28356383","id":"PMC_28356383","title":"Vigilin Regulates the Expression of the Stress-Induced Ligand MICB by Interacting with Its 5' Untranslated Region.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28356383","citation_count":9,"is_preprint":false},{"pmid":"15304008","id":"PMC_15304008","title":"Eight novel MICB alleles, including a null allele, identified in gastric MALT lymphoma patients.","date":"2004","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/15304008","citation_count":9,"is_preprint":false},{"pmid":"23479551","id":"PMC_23479551","title":"Metastamir-mediated immune evasion: miR-10b downregulates the stress-induced molecule MICB, hence avoid recognition by NKG2D receptor.","date":"2013","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/23479551","citation_count":9,"is_preprint":false},{"pmid":"21388352","id":"PMC_21388352","title":"Impact of MICA-TM, MICB-C1_2_A and C1_4_1 microsatellite polymorphisms on the susceptibility to chronic periodontitis in Germany.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21388352","citation_count":8,"is_preprint":false},{"pmid":"31435903","id":"PMC_31435903","title":"Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs.","date":"2019","source":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31435903","citation_count":8,"is_preprint":false},{"pmid":"32737971","id":"PMC_32737971","title":"Major Histocompatibility Complex Class I Chain-Related A and B (MICA and MICB) Gene, Allele, and Haplotype Associations With Dengue Infections in Ethnic Thais.","date":"2020","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32737971","citation_count":7,"is_preprint":false},{"pmid":"23380144","id":"PMC_23380144","title":"Characterization of 3'untranslated region (3'UTR) of the MICB gene.","date":"2013","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23380144","citation_count":7,"is_preprint":false},{"pmid":"36958849","id":"PMC_36958849","title":"Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC).","date":"2023","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36958849","citation_count":6,"is_preprint":false},{"pmid":"35525711","id":"PMC_35525711","title":"HLA class I chain-related MICA and MICB genes polymorphism in healthy individuals from the Bulgarian population.","date":"2022","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35525711","citation_count":6,"is_preprint":false},{"pmid":"27038471","id":"PMC_27038471","title":"In silico transcriptional regulation and functional analysis of dengue shock syndrome associated SNPs in PLCE1 and MICB genes.","date":"2016","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27038471","citation_count":6,"is_preprint":false},{"pmid":"23625227","id":"PMC_23625227","title":"Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance.","date":"2013","source":"Journal of microbiology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/23625227","citation_count":6,"is_preprint":false},{"pmid":"29665245","id":"PMC_29665245","title":"MICB*002 and MICB*014 protect against rheumatoid arthritis, whereas MICA*009 and MICA*A6 are associated with rheumatoid arthritis in a Hainan Han Chinese population.","date":"2018","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29665245","citation_count":5,"is_preprint":false},{"pmid":"25626490","id":"PMC_25626490","title":"Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.","date":"2015","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25626490","citation_count":5,"is_preprint":false},{"pmid":"12753668","id":"PMC_12753668","title":"Hyperkeratosis and leukocytosis in transgenic mice carrying MHC class I chain-related gene B (MICB).","date":"2003","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12753668","citation_count":5,"is_preprint":false},{"pmid":"27433477","id":"PMC_27433477","title":"Polymorphism rs3828903 within MICB Is Associated with Susceptibility to Systemic Lupus Erythematosus in a Northern Han Chinese Population.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27433477","citation_count":5,"is_preprint":false},{"pmid":"40954213","id":"PMC_40954213","title":"Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","date":"2025","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/40954213","citation_count":4,"is_preprint":false},{"pmid":"38205878","id":"PMC_38205878","title":"Linc-ROR inhibits NK cell-killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients.","date":"2024","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38205878","citation_count":4,"is_preprint":false},{"pmid":"37958261","id":"PMC_37958261","title":"Genetic Association Studies of MICB and PLCE1 with Severity of Dengue in Indonesian and Taiwanese Populations.","date":"2023","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37958261","citation_count":4,"is_preprint":false},{"pmid":"30471210","id":"PMC_30471210","title":"Diversity and characterisation of polymorphic 3' untranslated region haplotypes of MICA and MICB genes.","date":"2018","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/30471210","citation_count":4,"is_preprint":false},{"pmid":"39676862","id":"PMC_39676862","title":"Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39676862","citation_count":4,"is_preprint":false},{"pmid":"39871443","id":"PMC_39871443","title":"Identification of Novel MICB Alleles in Haematopoietic Stem Cell Donors of Indian Origin.","date":"2025","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/39871443","citation_count":4,"is_preprint":false},{"pmid":"30332343","id":"PMC_30332343","title":"Single-Nucleotide Polymorphisms in NOD1, RIPK2, MICB, PLCE1, TNF, and IKBKE Genes Associated with Symptomatic Dengue in Children from Colombia.","date":"2018","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30332343","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50162,"output_tokens":7316,"usd":0.130113,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16505,"output_tokens":4253,"usd":0.094425,"stage2_stop_reason":"end_turn"},"total_usd":0.224538,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MICA and MICB are stress-induced ligands recognized by gamma delta T cells expressing Vdelta1 on tumor cells. Vdelta1 gamma delta T cell lines and clones derived from tumors recognized MICA/B on autologous and heterologous tumor cells without constraints imposed by specific peptide ligands.\",\n      \"method\": \"T cell recognition assays using tumor-derived Vdelta1 gamma delta T cell lines and clones against autologous and heterologous tumor cells expressing MICA/B\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple tumor-derived T cell lines and clones tested against autologous and heterologous targets, replicated across multiple tumor types\",\n      \"pmids\": [\"10359807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NKG2D homodimers form stable complexes with monomeric MICA in solution without requiring additional components, and soluble NKG2D also binds to cell surface MICB. MICA glycosylation is not essential but enhances complex formation. Allelic variants of MICA show large differences in NKG2D binding associated with a single amino acid substitution at position 129 in the alpha2 domain.\",\n      \"method\": \"Solution binding assay (NKG2D homodimers with monomeric MICA), cell surface binding of soluble NKG2D to MICB-expressing cells, allelic variant comparison\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct reconstitution of NKG2D-MICA complex in solution, mutagenesis-level allelic comparison, multiple orthogonal methods\",\n      \"pmids\": [\"11491531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MICB is shed by metalloproteases from tumor cells, generating soluble MICB detectable in sera of cancer patients. Cell-bound MICB causes downregulation of surface NKG2D on NK cells, but soluble MICB did not alter NKG2D expression on NK cells in vitro.\",\n      \"method\": \"Metalloprotease inhibitor assays, ELISA for soluble MICB in patient sera, NK cell NKG2D expression assays with soluble MICB\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metalloprotease inhibitor experiments plus NK receptor downregulation assay, single lab\",\n      \"pmids\": [\"16698441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKG2D and MICB undergo intercellular transfer at the cytotoxic NK cell immune synapse (cNK-IS). MICB expressed on target cells induces clustering of NKG2D at the central supramolecular activation cluster. NKG2D transfer depended on binding to MICB. Transfer of MICB to NK cells also occurred, indicating bidirectional exchange. Brief interactions between NK cells and MICB-expressing target cells led to a reduction in NKG2D-dependent NK cytotoxicity.\",\n      \"method\": \"Live imaging of NK cell immune synapse, fluorescence microscopy, functional cytotoxicity assays with MICB-expressing 721.221 cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live imaging plus functional cytotoxicity assays, mechanistic specificity controls (other molecules not transferred), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16849432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HDAC inhibitor trichostatin A (TsA) increases MICA and MICB expression on leukemic cells by increasing histone H3 acetylation and decreasing HDAC1 association at the MICA and MICB promoters, as demonstrated by chromatin immunoprecipitation (ChIP) assay.\",\n      \"method\": \"ChIP assay for histone H3 acetylation and HDAC1 occupancy at MICA/MICB promoters; flow cytometry for surface expression; NK cytotoxicity assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP assay directly demonstrating chromatin remodeling at MICB promoter, coupled with functional NK killing assay, single lab\",\n      \"pmids\": [\"17625602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The MICB promoter contains a CCAAT box binding NF-Y and a GC box binding Sp1, Sp3, and Sp4. A MICB promoter polymorphism involving a 2-bp deletion near the CCAAT box and GC box diminishes Sp1 transcriptional activation, reducing MICB promoter activity 18-fold.\",\n      \"method\": \"Transcriptional reporter assays, electrophoretic mobility shift assays (EMSA), functional analysis of promoter variants\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted promoter activity by luciferase reporter, EMSA to identify binding proteins, functional mutagenesis of Sp1 site\",\n      \"pmids\": [\"17557375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Knockdown of Dicer in human cells elicits DNA damage and upregulates MICB expression. Upregulation of MICB by Dicer knockdown is prevented by pharmacological or genetic inhibition of ATM, ATR, or CHK1 kinases, placing MICB upregulation downstream of the DNA damage response pathway.\",\n      \"method\": \"RNAi knockdown of Dicer, pharmacological and genetic inhibition of ATM/ATR/CHK1, qRT-PCR and flow cytometry for MICB expression\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KD/inhibitor combinations), replicated with pharmacological and genetic approaches, single lab\",\n      \"pmids\": [\"18644891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"5-Aza-2'-deoxycytidine (5-aza-dC) induces MICB expression through promoter DNA demethylation and DNA damage; ATM kinase inhibition partially prevents MICB upregulation, demonstrating that both DNA damage signaling and demethylation contribute to 5-aza-dC-induced MICB expression.\",\n      \"method\": \"5-aza-dC treatment, bisulfite sequencing for promoter methylation, ATM inhibitor (KU55933) and ATM siRNA knockdown, flow cytometry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter methylation analysis plus genetic/pharmacological ATM inhibition, single lab\",\n      \"pmids\": [\"18395517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"microRNAs from multiple herpesviruses (HCMV, KSHV, EBV) directly target MICB mRNA at different but adjacent sites to repress its expression, enabling NK cell evasion. Despite no sequence homology among the viral miRNAs, they are functionally conserved in MICB suppression during authentic viral infection.\",\n      \"method\": \"Reporter assays with MICB 3'UTR, authentic viral infection experiments, NK cell killing assays\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct targeting of MICB 3'UTR by multiple viral miRNAs demonstrated by reporter assay and authentic infection, replicated across three different herpesviruses\",\n      \"pmids\": [\"19380116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of HCMV UL16 in complex with MICB at 1.8 Å resolution reveals that UL16 uses a three-stranded beta-sheet to engage the alpha-helical surface of the MICB platform domain, mimicking the NKG2D binding mode. UL16 binds MICB with nanomolar affinity (12-66 nM, by SPR). The inability of UL16 to bind MICA is due to a single residue difference: glutamine at position 169 in MICB (versus arginine in MICA) is critical for UL16 binding.\",\n      \"method\": \"X-ray crystallography (1.8 Å), surface plasmon resonance binding assays, mutational analysis of key residues\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure at high resolution combined with SPR quantitative binding and mutational validation, single study with multiple orthogonal methods\",\n      \"pmids\": [\"20090832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HHV-7 U21 protein downregulates the surface expression of MICB (and MICA), resulting in reduction of NK-mediated cytotoxicity. U21 can bind to ULBP1 and reroute it to the lysosomal compartment; the mechanism of MICA/B downregulation may involve similar lysosomal redirection.\",\n      \"method\": \"Flow cytometry for surface MICB/MICA expression in U21-expressing cells, NK cytotoxicity assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — flow cytometry showing surface downregulation plus NK killing functional assay, mechanism for MICB not as directly demonstrated as for ULBP1\",\n      \"pmids\": [\"22102813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-10b directly binds the 3'UTR of MICB mRNA and downregulates MICB surface expression. Antagonizing miR-10b enhanced NKG2D-mediated NK killing of tumor cells in vitro and tumor clearance in vivo; overexpression of miR-10b downregulated MICB and impaired NK cell elimination of tumor cells.\",\n      \"method\": \"Luciferase reporter assays with MICB 3'UTR, miR-10b overexpression and antagonism, flow cytometry, in vitro and in vivo NK killing assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct 3'UTR reporter validation plus loss- and gain-of-function in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22915757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HBsAg overexpression in HepG2 cells induces cellular miRNAs that repress MICA and MICB expression by targeting their 3'UTRs. Inhibiting these HBsAg-induced miRNAs partially restores MICA/MICB expression and increases NK cell-mediated cytolysis of HCC cells.\",\n      \"method\": \"miRNA profiling, 3'UTR reporter assays, miRNA inhibitors, NK cell cytotoxicity assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'UTR reporter validation plus functional NK killing assay with rescue by miRNA inhibitors, single lab\",\n      \"pmids\": [\"23917076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM15 mediates MICB ectodomain shedding in PANC-1 pancreatic cancer cells. Knockdown of ADAM15 upregulates cell surface MICB and reduces soluble MICB in culture supernatant. Gemcitabine suppresses ADAM15 expression, leading to increased surface MICB and decreased soluble MICB without changing MICB mRNA levels.\",\n      \"method\": \"ADAM15 siRNA knockdown, flow cytometry for surface MICB, ELISA for soluble MICB, qRT-PCR, gemcitabine treatment\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown of specific sheddase with direct measurement of surface vs. soluble MICB, mRNA control confirms post-translational mechanism, single lab\",\n      \"pmids\": [\"23314034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Six RNA-binding proteins (RBPs) that bind and regulate MICB expression were identified by unbiased RNA pull-down combined with mass spectrometry. At least two of the identified RBPs function during genotoxic stress to regulate MICB.\",\n      \"method\": \"RNA pull-down with MICB mRNA, mass spectrometry, functional validation of RBP knockdowns during genotoxic stress\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased pull-down plus mass spectrometry with functional validation, single lab\",\n      \"pmids\": [\"24924487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Valproic acid (VPA), an HDAC inhibitor, upregulates MICA and MICB surface expression on pancreatic cancer cells via the PI3K/Akt signaling pathway. This effect is blocked by the PI3K inhibitor LY294002 or siRNA targeting PI3KCA, and sensitizes cancer cells to NK-mediated killing in vitro and in vivo.\",\n      \"method\": \"PI3K inhibitor treatment (LY294002), siRNA knockdown of PI3KCA, flow cytometry for MICB surface expression, qRT-PCR, NK cytotoxicity assays, xenograft experiments\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement by pharmacological and genetic inhibition with functional NK killing readout, single lab\",\n      \"pmids\": [\"24885711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The RNA-binding protein IMP3 directly interacts with ULBP2 mRNA to destabilize it, and indirectly targets MICB through a mechanistically distinct pathway. IMP3-mediated regulation of MICB leads to impaired NK cell recognition of transformed cells.\",\n      \"method\": \"RNA pull-down, mRNA stability assays, IMP3 knockdown and overexpression, flow cytometry for MICB surface expression, NK cell killing assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RBP-RNA interaction for ULBP2, indirect MICB regulation with functional NK killing readout; MICB mechanism less directly defined, single lab\",\n      \"pmids\": [\"26982091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Vigilin, a multifunctional RNA-binding protein, binds to the 5'UTR of MICB mRNA and negatively regulates MICB expression. Vigilin knockdown in target cells increases MICB surface expression and enhances NK cell activation against those cells.\",\n      \"method\": \"RNA pull-down of MICB 5'UTR followed by mass spectrometry, vigilin knockdown, flow cytometry for MICB surface expression, NK cell activation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pull-down plus mass spectrometry with functional validation by KD and NK activation assay, single lab\",\n      \"pmids\": [\"28356383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"STAT3 inhibition by STA21 increases MICB cell surface expression and soluble MICB secretion by gastric adenocarcinoma cells. Recombinant soluble MICB decreases NKG2D receptor levels on NK and CD8+ T cells and impairs their cytotoxic function. MICB shedding in this context was not affected by metalloprotease inhibition, suggesting a non-metalloprotease secretory pathway.\",\n      \"method\": \"STAT3 inhibitor (STA21) treatment, flow cytometry, ELISA for soluble MICB, metalloprotease inhibitor assays, NK cell cytotoxicity assays\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological STAT3 inhibition with mechanistic controls (metalloprotease inhibitor negative result), functional NK killing assay, single lab\",\n      \"pmids\": [\"28917678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MICB and MICA expression is predominantly intracellular in both tumor and normal tissue, with only occasional evidence of cell membrane localization. No qualitative differences in cell surface expression were observed between tumor and MICA/B-expressing normal epithelia.\",\n      \"method\": \"Standard and confocal immunofluorescence microscopy using well-characterized antibodies on multiple human tumor and normal tissue samples\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic direct localization by confocal microscopy across multiple tissue types, single lab\",\n      \"pmids\": [\"28334733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DAC (decitabine) treatment of AML cells increases TIMP3 expression by demethylation of its promoter, and TIMP3 (an ADAM17 inhibitor) inhibits shedding of MICB (and MICA and ULBP2), reducing soluble NKG2D ligands and enhancing NK cell-mediated immune recognition of AML cells.\",\n      \"method\": \"Hypomethylating agent treatment, ADAM17 inhibitor (TIMP3) overexpression, ELISA for soluble MICB, NK cell killing assays, methylation analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway from demethylation to TIMP3 to ADAM17 inhibition to reduced MICB shedding, functional NK killing readout, single lab\",\n      \"pmids\": [\"28404876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Antibodies targeting the MICA α3 domain (site of proteolytic shedding) prevent proteolytic shedding of both MICA and MICB from human cancer cells, maintain cell surface MICA/MICB, inhibit tumor growth in immunocompetent mouse models, and reactivate NK cell antitumor immunity via NKG2D and CD16 Fc receptors.\",\n      \"method\": \"Rational antibody design targeting α3 domain, flow cytometry for surface MICA/MICB, in vivo tumor growth assays in immunocompetent mice, NK cell depletion experiments, humanized mouse model\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic targeting of shedding site with multiple in vivo models, NK depletion confirming effector mechanism, replicated across multiple tumor models\",\n      \"pmids\": [\"29599246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-34a plays a dual role in MICB regulation in hepatocytes: it can both increase MICB expression by upregulating ATR protein kinase and decrease MICB expression by downregulating the transcription factor E2F1. The net effect on MICB depends on endogenous E2F1 levels, with miR-34a promoting MICB in cells with low E2F1 (normal hepatocytes) but not in cells with high E2F1 (many HCC cells).\",\n      \"method\": \"miR-34a overexpression, ATR and E2F1 knockdown, flow cytometry, luciferase reporter assays, NK cell killing assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic perturbations (miRNA OE, ATR/E2F1 KD) with reporter assays and functional NK killing, single lab\",\n      \"pmids\": [\"30256916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MG132 (proteasome inhibitor) selectively upregulates MICB transcription in A549 lung cancer cells by acting at the 480-bp MICB upstream promoter. This upregulation requires ATM kinase, ATR kinase, and PI3K activity, as inhibitors of these kinases block MG132-induced MICB upregulation; MG132 activates CHK2 phosphorylation (a DNA damage marker), placing MICB upregulation downstream of the DNA damage response.\",\n      \"method\": \"MICB promoter luciferase reporter assay, ATM inhibitor (KU-55933), wortmannin, caffeine treatment, CHK2 phosphorylation assay, NK cytotoxicity blocking assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay with pharmacological epistasis analysis and DNA damage marker, single lab\",\n      \"pmids\": [\"30483783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Liver X receptor (LXR) activation upregulates MICB expression in multiple myeloma cells through inhibition of MICB protein degradation in lysosomes (post-translational stabilization), whereas MICA is regulated at the transcriptional level. LXR activation enhances NK cell-mediated killing of MM cells.\",\n      \"method\": \"LXR agonist treatment, MICB protein stability assays with lysosomal inhibitors, MICA promoter activity assays, NK cell killing assays, flow cytometry\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic distinction between MICA transcriptional vs. MICB lysosomal post-translational regulation using inhibitors and functional assays, single lab\",\n      \"pmids\": [\"31125275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Diverse allelic MICB proteins differentially bind the HCMV immunoevasin UL16. MICB*008, which contains methionine and asparagine at positions 98 and 113 in the alpha2 domain, shows decreased binding to UL16 compared to MICB*003, *004, and *00502 (which contain isoleucine and aspartic acid at those positions). UL16 variant strains did not affect binding activities.\",\n      \"method\": \"Production of soluble Fc-fusion UL16 proteins from four HCMV strains, stable cell lines expressing four MICB alleles, flow cytometry-based binding assays\",\n      \"journal\": \"Journal of microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — allele-specific binding by flow cytometry with multiple alleles and UL16 variants, functional interpretation regarding immune evasion, single lab\",\n      \"pmids\": [\"23625227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Missense variant MICB D136N (rs in MICB) expressed in cultured cells results in reduced surface MICB and reduced NKG2D ligation relative to wild-type MICB. Coculture of MICB D136N-expressing cells with NK cells results in less NKG2D activation and less susceptibility to NK cell killing compared to wild-type MICB-expressing cells.\",\n      \"method\": \"Expression of MICB missense variant protein in cultured cells, flow cytometry for surface MICB, NKG2D activation assays, NK cell coculture killing assays, ex vivo BAL analysis\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional characterization of missense variant with direct NKG2D activation assay and NK killing, supported by clinical association data, single lab\",\n      \"pmids\": [\"37878820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Transgenic mice ubiquitously expressing human MICB develop transient hyperkeratosis of the epidermis with infiltrating inflammatory cells, and a 50% increase in white blood cells, indicating that MICB expression in vivo is associated with skin inflammation and leukocytosis.\",\n      \"method\": \"Transgenic mouse generation with ubiquitous MICB promoter, histopathological analysis, complete blood count\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic in vivo loss-of-function/gain-of-function with histopathological phenotype, but limited mechanistic resolution of pathway, single lab\",\n      \"pmids\": [\"12753668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Nine novel miRNAs were identified that regulate MICB expression via both its 3'UTR and 5'UTR sequences in human cancer cells. Mutation of miRNA binding sites in both UTRs increased luciferase reporter activity, and overexpression/inhibition of candidate miRNAs decreased/increased MICB protein expression on cell surfaces.\",\n      \"method\": \"Luciferase reporter assays with MICB 3'UTR and 5'UTR constructs, site-directed mutagenesis of miRNA binding sites, miRNA overexpression and inhibition, flow cytometry\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reporter assay plus mutagenesis of binding sites plus gain/loss-of-function, single lab\",\n      \"pmids\": [\"28850101\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MICB is a stress-inducible MHC class I-related cell surface glycoprotein that serves as a ligand for the activating immunoreceptor NKG2D on NK cells, CD8+ T cells, and gamma-delta T cells; its expression is regulated at transcriptional level by Sp1/NF-Y binding to its promoter (modulated by HDAC activity and DNA methylation), at post-transcriptional level by multiple RNA-binding proteins (including vigilin via 5'UTR and IMP3) and miRNAs (including viral herpesvirus miRNAs, miR-10b, and cellular miRNAs targeting its 3'UTR), and at the protein level by metalloprotease-mediated ectodomain shedding (involving ADAM15 and ADAM17/TIMP3 axis), lysosomal degradation (regulated by LXR/cholesterol), and intracellular retention by viral immunoevasins such as HCMV UL16 (which engages the MICB alpha-helical platform domain at a glutamine-169-dependent interface); cell surface MICB activates NKG2D to trigger NK cytotoxicity, while proteolytic shedding generates soluble MICB that contributes to immune evasion by reducing NKG2D ligand density on tumor cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MICB is a stress-inducible MHC class I-related cell surface glycoprotein that functions as an activating ligand for the immunoreceptor NKG2D, engaging gamma-delta T cells, NK cells, and CD8+ T cells to trigger cytotoxicity against stressed and transformed cells [#0, #1, #3]. NKG2D homodimers bind monomeric MICB directly, and at the cytotoxic immune synapse MICB on target cells clusters NKG2D into the central supramolecular activation cluster, with bidirectional intercellular transfer of both molecules tuning the NK cytotoxic response [#1, #3]. MICB expression is controlled at multiple regulatory layers. Transcriptionally, the MICB promoter is driven by Sp1/Sp3/Sp4 at a GC box and NF-Y at a CCAAT box, and is modulated by chromatin state, since HDAC inhibition raises histone H3 acetylation and lowers HDAC1 occupancy at the promoter, while promoter demethylation also induces expression [#5, #4, #7]; genotoxic stress couples MICB induction to the ATM/ATR/CHK1 DNA damage response [#6, #23]. Post-transcriptionally, MICB mRNA is repressed by RNA-binding proteins acting through its 5'UTR (vigilin) and by IMP3, and by numerous miRNAs—including functionally convergent herpesviral miRNAs (HCMV, KSHV, EBV) and cellular miRNAs such as miR-10b—targeting its 3'UTR and 5'UTR [#17, #16, #8, #11, #28]. At the protein level, MICB is shed from the cell surface by metalloproteases including ADAM15 and the ADAM17/TIMP3 axis, generating soluble MICB that contributes to immune evasion; antibodies blocking the shedding site preserve surface MICB and reactivate NK antitumor immunity in vivo [#13, #20, #2, #21]. Viral immunoevasins additionally subvert MICB: HCMV UL16 engages the alpha-helical platform domain via a glutamine-169-dependent interface that mimics the NKG2D binding mode and retains MICB intracellularly, with allelic MICB variants differing in UL16 binding [#9, #25]. A naturally occurring MICB D136N missense variant reduces surface expression and NKG2D ligation, blunting NK killing [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established MICB as a stress-induced cell surface ligand recognized by the immune system, defining its role in immune surveillance of tumors independent of peptide presentation.\",\n      \"evidence\": \"Vdelta1 gamma-delta T cell recognition assays against autologous and heterologous tumor cells expressing MICA/B\",\n      \"pmids\": [\"10359807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the activating receptor responsible for recognition\", \"Did not resolve how MICB induction is triggered\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified NKG2D as the receptor binding MICB directly, providing the molecular basis for MICB-driven immune activation.\",\n      \"evidence\": \"Solution binding of NKG2D homodimers to MICA, soluble NKG2D binding to surface MICB, allelic variant comparison\",\n      \"pmids\": [\"11491531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Affinity and structural detail of NKG2D-MICB itself not fully quantified\", \"Downstream signaling consequences not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed MICB engagement at the NK immune synapse drives NKG2D clustering and bidirectional transfer, revealing a self-limiting feature of MICB-mediated activation, while metalloprotease shedding generates soluble MICB in patient sera.\",\n      \"evidence\": \"Live synapse imaging, cytotoxicity assays with MICB-expressing target cells; metalloprotease inhibitor assays and serum ELISA\",\n      \"pmids\": [\"16849432\", \"16698441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the shedding metalloprotease not defined\", \"Functional consequence of soluble MICB on NK cells unclear (no NKG2D downregulation observed)\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the transcriptional architecture of the MICB promoter (Sp1/NF-Y) and demonstrated chromatin-level control via histone acetylation and HDAC1 occupancy.\",\n      \"evidence\": \"Promoter reporter assays, EMSA, promoter polymorphism analysis; ChIP for H3 acetylation and HDAC1 at the MICB promoter\",\n      \"pmids\": [\"17557375\", \"17625602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that recruit HDAC1 versus activators not defined\", \"Connection between promoter occupancy and physiological stress unaddressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed MICB induction downstream of the ATM/ATR/CHK1 DNA damage response and linked it to promoter demethylation, establishing genotoxic stress as a trigger of MICB surface expression.\",\n      \"evidence\": \"Dicer knockdown with ATM/ATR/CHK1 inhibition; 5-aza-dC treatment with bisulfite sequencing and ATM inhibition\",\n      \"pmids\": [\"18644891\", \"18395517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular step coupling DDR kinases to MICB transcription not identified\", \"Relative contribution of transcriptional versus post-transcriptional DDR control unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed convergent post-transcriptional immune evasion: structurally unrelated herpesviral miRNAs target the MICB 3'UTR to suppress NK recognition during infection.\",\n      \"evidence\": \"MICB 3'UTR reporter assays, authentic HCMV/KSHV/EBV infection, NK killing assays\",\n      \"pmids\": [\"19380116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selective pressure driving 3'UTR targeting not defined\", \"Interplay with host miRNA regulation unaddressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined at atomic resolution how the HCMV UL16 immunoevasin captures MICB via the NKG2D-mimicking platform domain, pinpointing glutamine-169 as the allele-specific determinant.\",\n      \"evidence\": \"X-ray crystallography at 1.8 A, surface plasmon resonance, mutational analysis\",\n      \"pmids\": [\"20090832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular retention mechanism downstream of binding not structurally resolved\", \"Generalizability to other immunoevasins not established here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded the regulatory repertoire to specific sheddases and additional viral evaders, and established allele-dependent UL16 binding among MICB variants.\",\n      \"evidence\": \"ADAM15 knockdown with surface/soluble MICB measurement; HBsAg-induced miRNA profiling; HHV-7 U21 surface downregulation; allele-specific UL16 Fc-fusion binding assays\",\n      \"pmids\": [\"23314034\", \"23917076\", \"22102813\", \"23625227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether multiple sheddases act redundantly on MICB unresolved\", \"U21 lysosomal mechanism for MICB inferred from ULBP1, not directly shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified RNA-binding proteins (including vigilin via the 5'UTR and IMP3) as direct post-transcriptional repressors of MICB linking RNA metabolism to NK evasion.\",\n      \"evidence\": \"RNA pull-down with mass spectrometry, knockdown, surface MICB flow cytometry, NK assays (multiple studies)\",\n      \"pmids\": [\"24924487\", \"26982091\", \"28356383\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"IMP3 effect on MICB is indirect and mechanistically undefined\", \"Coordination among the multiple RBPs not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Refined the spatial and signaling control of MICB, showing predominantly intracellular localization, STAT3- and PI3K/Akt-linked modulation, and extensive multi-miRNA targeting of both UTRs.\",\n      \"evidence\": \"Confocal microscopy of tumor/normal tissue; STAT3 and PI3K inhibitor studies with NK assays; dual-UTR luciferase reporters with binding-site mutagenesis\",\n      \"pmids\": [\"28334733\", \"28917678\", \"24885711\", \"28850101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism routing MICB to the surface from intracellular pools not defined\", \"Non-metalloprotease MICB secretion pathway uncharacterized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established protein-level stabilization strategies and therapeutic proof-of-concept: blocking shedding or stabilizing MICB protein preserves surface ligand and reactivates antitumor immunity.\",\n      \"evidence\": \"Anti-alpha3-domain shedding-blocking antibodies in immunocompetent mice with NK depletion; miR-34a/ATR/E2F1 perturbations; (2019) LXR-driven lysosomal MICB stabilization\",\n      \"pmids\": [\"29599246\", \"30256916\", \"31125275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lysosomal degradation machinery for MICB not molecularly defined\", \"Context-dependence of miR-34a dual effect across tumor types unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that natural MICB coding variation functionally tunes NKG2D ligation and NK killing, linking MICB genotype to immune outcomes.\",\n      \"evidence\": \"Expression of MICB D136N missense variant, surface flow cytometry, NKG2D activation and NK coculture killing assays\",\n      \"pmids\": [\"37878820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for reduced surface expression of D136N not defined\", \"Population-level immune consequences not established mechanistically\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse transcriptional, RNA-binding, miRNA, shedding, and trafficking inputs are integrated to set MICB surface density on a given stressed cell remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model coupling DDR signaling to specific surface-trafficking steps\", \"Mechanism controlling intracellular retention versus surface display of MICB undefined\", \"Relative quantitative contribution of each regulatory layer in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 3, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 3, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [19, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 8]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 7, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KLRK1\",\n      \"UL16\",\n      \"ADAM15\",\n      \"ADAM17\",\n      \"TIMP3\",\n      \"HDLBP\",\n      \"IGF2BP3\",\n      \"SP1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}